Dr Bardia on T-DXd Efficacy By Pace of Prior CDK4/6 Inhibitor Progression in Breast Cancer
Автор: OncLive
Загружено: 2024-12-10
Просмотров: 132
Описание:
Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in HER2-low/ultralow metastatic breast cancer by disease progression on prior therapy.
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center, discusses findings from an analysis of the phase 3 DESTINY-Breast06 trial (NCT04494425) investigating the efficacy of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) compared with physician’s choice of chemotherapy in patients with hormone receptor (HR)–positive, HER2-low or -ultralow metastatic breast cancer who were stratified by pace of disease progression on prior endocrine therapy plus a CDK4/6 inhibitor.
See our site for more from SABCS: https://www.onclive.com/conference/sabcs
Website: https://www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
